%D9%85%D8%AA%D9%84%D8%A7%D8%B2%D9%85%D8%A9_%D9%81%D8%B1%D8%B7_%D8%A7%D9%84%D8%AA%D9%86%D8%A8%D9%8A%D9%87_%D8%A7%D9%84%D9%85%D8%A8%D9%8A%D8%B6%D9%8AOvarielles_HyperstimulationssyndromOvarian_hyperstimulation_syndromeS%C3%ADndrome_de_hiperestimulaci%C3%B3n_ov%C3%A1ricoSiondr%C3%B3m_forubhsceite%D7%AA%D7%A1%D7%9E%D7%95%D7%A0%D7%AA_%D7%92%D7%99%D7%A8%D7%95%D7%99_%D7%99%D7%AA%D7%A8_%D7%A9%D7%97%D7%9C%D7%AA%D7%99%E5%8D%B5%E5%B7%A3%E9%81%8E%E5%89%B0%E5%88%BA%E6%BF%80%E7%97%87%E5%80%99%E7%BE%A4S%C3%ADndrome_de_hiperestimula%C3%A7%C3%A3o_ovarianaOvariellt_hyperstimuleringssyndromQ1760461
about
Comparison Between GnRH Agonist and GnRH Antagonist Protocols of Ovarian Stimulation in PCOS PatientsTransfer of Fresh Versus Frozen/Thawed Embryos in IVF Cycles Where GnRH Agonist is Utilized for Oocyte Maturation.Endometrial Receptivity After GnRH Agonist TriggeringFSH in GnRH-AntagoniST Controlled Ovarian Hyperstimulation Cycles (FAST)The Role of Cetrotide Acetate in Prevention of Ovarian Hyperstimulation Syndrome (OHSS) in Oocyte DonorsHormone Evaluation in Artificial Reproductive TechnologyClinical Study of Recombinant Human Follitropin for Injection Assisted in COH Assisted IVF-ETDouble GnRH Antagonist Daily Dose in Hyperresponding IVF/ICSI Cycles May Prevent the OHSSCalcium for Prevention of Ovarian Hyperstimulation SyndromeResveratrol as a Preventive Treatment of OHSSThe Effectiveness and Safety of the Prolonged Down-regulation Protocol for Controlled Ovarian HyperstimulationMontelukast for Prevention & Treatment of OHSSEffects of Controlled Ovarian Hyperstimulation (COH) With Letrozole and GonadotropinThe Four Methods of Ovarian Stimulation in Patients With Polycystic Ovarian SyndromeGnRH Antagonist for Treatment of Early Ovarian Hyperstimulation SyndromeAdministration of Increased Dose of GnRH Antagonist for Coasting for Decreasing the Risk for Ovarian Hyperstimulation Syndrome( OHSS)Gene Expression Profile After Gonadotropin Releasing Hormone (GnRH) Agonist Trigger of Oocyte MaturationInvestigate Dose of Org 36286 to Initiate Multiple Follicular Growth in a Controlled Ovarian Hyperstimulation Protocol for IVF or IVF/ICSI (P07015)Long Acting GnRH Antagonist in PCOS Women Undergoing IVFRepeated Injection of GnRH Agonist to Reduce Ovarian Hyperstimulation SyndromeDual Trigger to Reduce Ovarian Hyperstimulation SyndromeCabergoline and Coasting to Prevent OHSSThe Effect of a Dual Trigger on Intracytoplasmic Sperm Injection (ICSI) Reproductive OutcomesLuteal Antagonist Versus Conventional Treatment in Women With Severe Early Ovarian Hyperstimulation Syndrome (OHSS)Routine Hysteroscopy in IVF/ICSI Cycles in Patients With Primary Unexplained InfertilityCalcium Dobesilate Versus Coasting for Prevention of Ovarian Hyperstimulation SyndromeCalcium Dobesilate Versus Cabergoline for Prevention of Ovarian Hyperstimulation SyndromeStudy of Serum Levels of Oxidative Stress Markers in Ovarian Hyperstimulation PatientsLuteal Phase Supplementation With Recombinant LH After GnRh Agonist Oocytes Triggering in Women at Risk of OHSSCo-administration of Low Dose hCG at the Time of GnRH Agonist Trigger or 35 Hours Later for the Prevention of OHSSCan GnRH Agonist Trigger Prevent Ovarian Hyperstimulation Syndrome?GnRH Agonist (GnRHa) Withdrawal at Late Stage of Long Protocol and the Incidence of Ovarian Hyper-stimulationOvarian Hyperstimulation Syndrome and CabergolineCabergoline and Hydroxyethyl Starch in Ovarian Hyperstimulation Syndrome PreventionA Comparative Study of Two Patterns of Controlled Ovarian Hyperstimulation in Mid Follicular Phase or Early Luteal Phase for Egg DonorsPheno- & Genotyping POF (WHO III)Administration of Methylprednisolone for Prevention of Ovarian Hyper Stimulation SyndromeCompare the Efficacy of Human Albumin With Cabergoline to Prevent Ovarian Hyper Stimulation in Assisted Reproductive Technology (ART) ProgramStudy of Cabergoline for Prevention of Ovarian Hyperstimulation Syndrome (OHSS) in In Vito Fertilization Cycles and Derivation of OHSS BiomarkersOvarian Hyperstimulation Syndrome (OHSS) Prevention With Agonist
P1050
P2175
P2293
Optimal usage of the GnRH antagonists: a review of the literaturePharmacologic Interventions in Preventing Ovarian Hyperstimulation Syndrome: A Systematic Review and Network Meta-AnalysisPredicting and preventing ovarian hyperstimulation syndrome (OHSS): the need for individualized not standardized treatment.Does freeze all policy eliminate OHSS??? "It ain't necessarily so…".Safety of Follitropin Alfa/Lutropin Alfa for Stimulation of Follicular DevelopmentComparison Between GnRH Agonist and GnRH Antagonist Protocols of Ovarian Stimulation in PCOS PatientsThe Influence of Dopamine Agonist Cabergoline on Oocyte MaturationEndometrial Receptivity After GnRH Agonist TriggeringEvaluation of the Optimal Dose of GnRH Agonist for Triggering Final Oocyte Maturation in High Risk OHSS PatientsDouble GnRH Antagonist Daily Dose in Hyperresponding IVF/ICSI Cycles May Prevent the OHSSCalcium for Prevention of Ovarian Hyperstimulation SyndromehMG or Recombinant FSH on OHSS Prevention in PCOS Patients Undergoing IVFMetformin in High Responder Polycystic Ovary Syndrome (PCOS) Patients Undergoing IVF CyclesResveratrol as a Preventive Treatment of OHSSHigher melatonin in the follicle fluid and MT2 expression in the granulosa cells contribute to the OHSS occurrenceSubstantial Effect of Fenugreek Seeds Aqueous Extract on Serum Estradiol Level in Ovarian Hyperstimulation Syndrome Rat ModelCauses of Massive Vulvar Edema in Patients with Severe Ovarian Hyperstimulation Syndrome: A Case Report and Literature ReviewIn-vitro fertilization resulting in heterotopic pregnancy, ovarian hyperstimulation and paralytic ileus: A case reportDual Trigger, Urinary HCG or Recombinant HCG, Which is the Best !?Management of Ovarian Hyperstimulation Syndrome as a State of Defective Mineralocorticoid Response
P921
Q61922319-A5CC9C1F-9FE1-4C80-AB4F-192EDC6026FBQ61934399-300AAC3D-1F8B-4B23-BBCF-76C5F8791B4AQ61957659-94A87393-B71A-4D96-B9B5-6F84907B1617Q61975453-BC15F76D-3E35-4873-BDF6-5F55A0BE1672Q61980877-56DA2BAA-0E15-4406-92A6-EF27D9360412Q62035416-F4117581-8019-4594-91F3-69E3742C3EDBQ63229043-46F0B886-5C96-4055-99D5-D515C427A20FQ63320358-C821AE24-378A-4B34-AB72-73712662F00DQ63320913-35563EBE-BC3A-4B12-B308-5B7ABF00EF5AQ63401748-9C1F6A31-0CBE-43D5-A1A0-D80823AF15D4Q63583878-A0E2EA08-2864-40B5-996E-2F324F9742B6Q63593632-D306AFB2-F43D-4FF8-912E-A1B79D52197DQ63807044-DCB68EEE-E58D-4FC0-832E-3872A6AB86FFQ63808531-B24249A3-AABA-4D4F-964D-B524BDB5A53AQ63816255-16D3E755-E9F5-4749-84D1-E765FF25EF19Q63833282-CC0FD94E-6F49-462D-B5C6-348DD6F52DCEQ63842869-9192223E-1D55-404E-B059-C9EA327EE316Q64042434-47A2F16F-D320-4647-83D1-307D2E62BCB6Q64221508-42EED510-AF35-4DA0-AD34-DD58639B6024Q64350208-3ADE1F61-2A5F-426F-AC8D-BC01F46ED38DQ64350211-F8F74383-6216-4697-A63D-EDB0F63367E4Q64352206-DE9E3F83-76CB-4B0B-B414-5D9258D4C46BQ64352652-4E9EB598-09F4-48B5-B1FB-6F626EDA1217Q64392388-9D3A59A9-1625-4ADD-BB9C-EB639DC1D25CQ64396171-27E6C2ED-5FF7-48B6-8974-98A470975144Q64599130-41E0F128-E145-47CD-8B73-A8986F1CE437Q64601374-987169FE-6EF4-4532-8D41-7B16806857ACQ64609110-3227AAE2-5C16-4EFA-B0CB-D396221D5E99Q64609356-22390EC5-EBE3-4FC8-AAFE-88F3E112E58CQ64631634-ACCF9FB7-222F-47E1-8217-3CC424AADB45Q64638327-25BB9B98-994D-46F4-BEEA-A5252DB2F143Q64643140-117B6DAF-7442-44A2-B9B7-6CD58C5C9B0EQ64644926-8FC0249C-5CEF-469C-8682-839040F99D26Q64646849-2C0A2959-8D08-40D8-8F1B-4F4479EAED13Q64649589-80CDB154-9F48-43ED-A334-7D29BE39DCEEQ64660477-2AE6410D-F51B-4EF3-8E1D-50B6A8DB8B7DQ64666397-D2C2B285-D28D-4C0A-9327-B0999D320CDCQ64666520-5E5D2BD4-8CD8-4CA2-B225-8BA4C472906BQ64672419-E232657E-FE6C-4EE3-85D9-D8688B350D14Q64694815-87703241-5935-41A4-81F0-485D0DC2C5CC
P1050
Q21245566-99A9B807-E38F-4A5C-963E-2F8F6810228EQ28073087-6D03D671-4A7A-4804-863B-969753D321CAQ36112513-E5EF23AC-715B-48EC-A842-A73ED9ABB304Q43206166-4b72640a-4de9-d3fc-f4f0-5c4d0c87195aQ57809883-B20BF588-E566-4362-AF38-B75662DF556DQ61922319-187EE4D7-DDFC-408F-8E2D-D94885B57B20Q61939376-5A4CE01D-0D03-4F12-81E1-06E5D235F4D6Q61957659-4E415CA3-7DED-4649-BEFC-D88D64CCEA89Q61975086-30C31A36-0142-4FA8-8FD6-BEBA395C918CQ63320358-978723EE-F8FF-4F51-97C5-9A3F69DB4A4CQ63320913-8F96510F-2D77-4F88-A361-E0C86464D5B2Q63333716-5EB513B7-B88D-4D3D-B26C-C476B65340E3Q63340937-5B9808F9-F067-4B8C-B90E-1A962066307BQ63401748-94E77AA7-4E11-46CE-BA93-B0CC4874CBEDQ64052712-1EE87CD9-67C8-4CE8-AB3D-EBBFC4E1232EQ64076531-5239A6E4-35C7-4923-B9B7-1F4CC1DF944DQ64107978-200BD37F-5CB7-4558-A35E-C77EB21D8A64Q64111422-BE817E65-E651-4897-BFE2-D39F1E7BFFF9Q86311141-5CE2A5AA-F2A4-4F81-B36F-748387E5D381Q93581714-AD99D708-2A60-40BE-82B6-13CB5F7598B8
P921
description
Human disease
@en
Krankheitsbild durch Stimulation der Follikelanbildung mittels Gonadotropinen
@de
nezánětlivé onemocnění ženského pohlavního ústrojí
@cs
مرض يصيب الإنسان
@ar
name
ovarian hyperstimulation syndrome
@en
ovarielles Hyperstimulationssyndrom
@de
ovariellt hyperstimuleringssyndrom
@sv
siondróm forubhsceite
@ga
syndrom ovariální hyperstimulace
@cs
syndrome d'hyperstimulation ovarienne
@fr
síndrome de hiperestimulación ovárico
@es
síndrome de hiperestimulação ovariana
@pt
תסמונת גירוי יתר שחלתי
@he
متلازمة فرط التنبيه المبيضي
@ar
type
label
ovarian hyperstimulation syndrome
@en
ovarielles Hyperstimulationssyndrom
@de
ovariellt hyperstimuleringssyndrom
@sv
siondróm forubhsceite
@ga
syndrom ovariální hyperstimulace
@cs
syndrome d'hyperstimulation ovarienne
@fr
síndrome de hiperestimulación ovárico
@es
síndrome de hiperestimulação ovariana
@pt
תסמונת גירוי יתר שחלתי
@he
متلازمة فرط التنبيه المبيضي
@ar
altLabel
Hyperstimulationssyndrom
@de
Hyperstimulering
@sv
OHSS
@ar
OHSS
@de
OHSS
@en
OHSS
@es
OHSS
@sv
Ovarian Hyperstimulation Syndrome, Familial Gestational Spontaneous
@en
secondary Meig's syndrome
@en
Überstimulationssyndrom
@de
prefLabel
ovarian hyperstimulation syndrome
@en
ovarielles Hyperstimulationssyndrom
@de
ovariellt hyperstimuleringssyndrom
@sv
siondróm forubhsceite
@ga
syndrom ovariální hyperstimulace
@cs
syndrome d'hyperstimulation ovarienne
@fr
síndrome de hiperestimulación ovárico
@es
síndrome de hiperestimulação ovariana
@pt
תסמונת גירוי יתר שחלתי
@he
متلازمة فرط التنبيه المبيضي
@ar
P279
P2888
P486
P5806
P6366
P646
P1461
Ovarian-Hyperstimulation-Syndrome
P1550
P1692
P1995
P2176
P2293
P279
P2892
P3827
ovarian-hyperstimulation-syndrome